Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Pharm Res. 2015 May 6;32(10):3170–3187. doi: 10.1007/s11095-015-1695-1

Table 3.

Deposition fractions (as a percentage of aerosolized dose) based on CFD predictions compared with the in vivo data of Newman et al. (51) (in parentheses) for the Novolizer operated with a QD waveform and PIFR of 99 LPM.

MP+MT 67 (66.5)
Central lung (trachea excluded) 9.0 (10.6)
Intermediate and peripheral lung 22.1 (19.4)
Trachea-B3 2.7
B4-B7 8.2
B8-B15 1.8
Alveolar 20.3